載入中
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
最新資料
¥1,183
−¥37.00 · -3.03%
盤中時間採用JST。市場資料可能有所延遲。
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
日內區間
目前¥1,183
52週區間
目前¥1,183
盤中時間採用JST。市場資料可能有所延遲。
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
日內區間
目前¥1,183
52週區間
目前¥1,183
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（JPY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 296.15億 JPY | 288.35億 JPY | 127.66億 JPY | 155.69億 JPY | 177.12億 JPY |
| 銷貨成本 | 81.98億 JPY | 107.07億 JPY | 49億 JPY | 17.68億 JPY | 17.35億 JPY |
| 毛利 | 214.17億 JPY | 181.28億 JPY | 78.66億 JPY | 138.01億 JPY | 159.77億 JPY |
| 研究與開發 | 144.66億 JPY | 118.16億 JPY | 100.75億 JPY | 74.54億 JPY | 59.31億 JPY |
| 銷售、一般及管理費用 | 152.25億 JPY | 116.76億 JPY | 68.51億 JPY | 35.35億 JPY | 31.38億 JPY |
| 營業費用 | 296.91億 JPY | 234.92億 JPY | 169.26億 JPY | 109.89億 JPY | 90.69億 JPY |
| 利息收入 | 9.87億 JPY | 14.78億 JPY | 12.25億 JPY | 2.36億 JPY | 400萬 JPY |
| 利息支出 | 74.75億 JPY | 7.77億 JPY | 8.03億 JPY | 7.15億 JPY | 5.28億 JPY |
| 折舊和攤銷 | 43.66億 JPY | 39.84億 JPY | 24.78億 JPY | 13.45億 JPY | 12.78億 JPY |
| 營業利益 | −82.74億 JPY | −53.64億 JPY | −90.6億 JPY | 28.12億 JPY | 69.08億 JPY |
| 淨利 | −125.3億 JPY | −48.38億 JPY | −71.93億 JPY | 3.82億 JPY | 10.17億 JPY |
公司資料更新於 2026年10月14日。
近期已公布業績
近期已公布業績
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2015年3月27日 | ¥10.00Special | — | — |
除息 2015年3月27日
¥10.00
Special
報告持有此股票曝險的交易所交易基金。
NEXT FUNDS TOPIX Exchange Traded Fund1306.T36.63億0.01%35.17兆 JPY0.05%¥431.3-0.28%
iShares Core TOPIX ETF1475.T3.19億0.01%3.01兆 JPY0.05%¥425-0.21%
Vanguard Total International Stock ETFVXUS753.1萬0.00%6657億 USD0.05%US$84.54+0.12%
Vanguard FTSE Developed Markets ETFVEA490.02萬0.00%3238億 USD0.03%US$70.06+0.16%
Dimensional - International Small Cap ETFDFIS243.02萬0.04%57.73億 USD0.39%US$36.09+0.45%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS226.09萬0.01%145億 USD0.06%US$154.25+0.07%
Schwab International Small-Cap Equity ETFSCHC112.61萬0.02%55.18億 USD0.06%US$49.30+0.35%
Dimensional - International Core Equity 2 ETFDFIC72.33萬0.00%151.57億 USD0.22%US$37.68+0.56%NEXT FUNDS TOPIX Exchange Traded Fund1306.TiShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEADimensional - International Small Cap ETFDFISVanguard FTSE All-World ex-US Small-Cap ETFVSSSchwab International Small-Cap Equity ETFSCHCDimensional - International Core Equity 2 ETFDFICAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
